Welcome to our dedicated page for Tiziana Life Sciences Com news (Ticker: TLSA), a resource for investors and traders seeking the latest updates and insights on Tiziana Life Sciences Com stock.
Tiziana Life Sciences Ltd. develops intranasal foralumab, a fully human anti-CD3 monoclonal antibody, as a clinical-stage biotechnology company focused on neuroinflammatory and neurodegenerative diseases. News for TLSA centers on clinical and preclinical data for intranasal anti-CD3 therapy, including non-active secondary progressive multiple sclerosis, Multiple System Atrophy, Alzheimer’s disease, ALS, Long COVID-associated neuroinflammation, and age-related cognitive decline.
Company updates also cover biomarker work involving CSF proteomics, TSPO-PET and microglial activation, peer-reviewed publications, scientific conference presentations, expanded-access observations, and financing actions such as registered direct offerings of ordinary shares and warrants.
Tiziana Life Sciences (NASDAQ: TLSA) has announced a new analyst research note published by H.C. Wainwright & Co., available on their website. The company focuses on developing novel therapies for oncology, inflammation, and infectious diseases. Tiziana is advancing its pipeline, including phase 2 studies for foralumab, a human anti-CD3 monoclonal antibody targeting Crohn’s Disease and multiple sclerosis. They are also accelerating development of an anti-IL6R monoclonal antibody aimed at treating IL6-induced inflammation, particularly in COVID-19 patients.
Tiziana Life Sciences (NASDAQ: TLSA) announced a collaborative clinical study for the nasal administration of Foralumab in COVID-19 patients in Brazil, aimed at reducing severe symptoms associated with the disease. The study is anticipated to start soon, with preliminary data expected by the end of 2020. Foralumab, a fully human anti-CD3 monoclonal antibody, has shown promise in modulating the immune system, particularly in mitigating cytokine storms that lead to respiratory failure. The innovative approach may significantly impact COVID-19 treatment strategies.
Tiziana Life Sciences (TLSA) announced plans to demerge its StemPrintER asset into Accustem Sciences Limited, an independently listed public company. StemPrintER, a genomic-based assay, is noted for its 40% higher accuracy compared to the Oncotype DX assay for predicting breast cancer recurrence. A shareholder meeting is scheduled for October 2, 2020, with a record date for a 1:1 share dividend on October 30, 2020. Accustem aims for a late Q4 2020 listing on the London Stock Exchange and plans to seek CE Mark approval in November.
Tiziana Life Sciences Plc (LSE: TILS, NASDAQ: TLSA) announced a strategic demerger of its genomics-based business, StemPrintER, into a new company named Accustem Sciences Limited. This decision aims to enhance the commercialization of the StemPrintER platform with an approximate cash reserve of £1 million. The demerger requires court-approved capital reduction and involves a series of meetings and hearings planned for October 2020. Shareholders will receive shares in Accustem based on their holdings in Tiziana during the demerger record time, promoting better focus on both entities' growth strategies.
Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) clarified its filing of a corrected amendment registration statement on Form F-6, which is not for a capital raise but to increase the number of American Depositary Shares (ADSs) for shareholder exchange. Each ADS represents two ordinary shares, and the trend of ordinary shares being exchanged for ADSs has grown recently. The company is also focused on developing drugs for various diseases, including Crohn’s disease and COVID-19, through its novel therapeutic candidates.
Tiziana Life Sciences (TLSA) announced a CEO interview detailing recent patent issuances, including anti-CD3 monoclonal antibodies for Crohn’s Disease and anti-IL-6 monoclonal antibodies for COVID-19. Key points discussed include the clinical pipeline for Foralumab and TZLS-501, intended for treating severe COVID-19 and hepatocellular carcinoma using Milciclib. Tiziana emphasizes its unique position with the fully human monoclonal antibody Foralumab in clinical development. The company is advancing its drug candidates aimed at various diseases.
Tiziana Life Sciences (Nasdaq: TLSA) announced the grant of a patent (No. 10,759,862) by the USPTO for its fully human monoclonal antibody, TZLS-501, aimed at treating COVID-19 and other pulmonary diseases. This antibody targets both IL-6R and IL-6, potentially alleviating cytokine storms in patients. The company plans to expedite clinical development, including GMP manufacturing and toxicology studies, to file an IND for clinical trials by Q1 2021. The patent strengthens Tiziana's IP portfolio as it seeks to utilize inhalation delivery for effective treatment.
Tiziana Life Sciences (Nasdaq: TLSA) announced that the USPTO granted a patent for the combination use of Milciclib with tyrosine kinase inhibitors (TKIs) for treating hepatocellular carcinoma (HCC). This patent (No. 10,758,541) will be published on September 1, 2020. Recent presentations at ASCO2020 highlighted Milciclib's favorable tolerance and promising activity in sorafenib-resistant HCC patients. The company aims to advance clinical evaluations for advanced and recurrent HCC cases. Dr. Shailubhai emphasized the need for combination therapies to overcome drug resistance in HCC.
Tiziana Life Sciences (Nasdaq: TLSA) has been granted a patent by the USPTO for treating Crohn’s disease with Foralumab, a fully human monoclonal antibody. This patent, effective from September 1, 2020, enhances the company's intellectual property portfolio. Tiziana's Phase 1 trial indicated Foralumab’s oral administration was well-tolerated, leading to plans for a Phase 2 trial for moderate-to-severe Crohn’s patients later this year. The innovative oral and nasal delivery methods aim to reduce toxicity and enhance treatment efficacy.
Tiziana Life Sciences (Nasdaq: TLSA) announced management team participation in the BTIG Biotechnology Conference on August 11, 2020, at 2:30 p.m. EDT. The event can be accessed through a live webcast via registration. Tiziana is focused on developing targeted drugs for cancer, inflammatory diseases, and COVID-19, with foralumab entering phase 2 studies for conditions like Crohn’s Disease and multiple sclerosis.
Foralumab is the world's only fully human anti-CD3 mAb in clinical development, with applications in autoimmune diseases.